Reply to the Editor  by Weder, Walter
Catamenial pneumothorax: Some
commentaries
To the Editor:
We read with interest the article by Korom
and associates1 reporting 3 new cases of cata-
menial pneumothorax and with an excellent
review of the literature. The reports outline
the frequent lack of recognition of diaphrag-
matic endometriosis as the causative factor of
catamenial pneumothorax, even in patients
submitted to surgical exploration with video-
assisted thoracoscopy. In a previous prospec-
tive study on catamenial pneumothorax,2 we
pointed out that exploration of the whole
thoracic cavity should be mandatory in these
patients. We suggested that patients should
be positioned in the posterolateral decubitus
position to correctly explore the whole hemi-
diaphragm, which is often incompletely visu-
alized if the patient is positioned as for a
lateral thoracotomy.
We would like to comment on 2 points
concerning the article by Korom and associ-
ates.1 First, they state that not all of a pa-
tient’s menses coincide with a pneumotho-
rax, but each episode of a catamenial
pneumothorax is associated with the men-
strual flow. Definition of catamenial pneumo-
thorax implies a strict temporal relationship
with menses, and the condition has been of-
ten defined as a recurrent pneumothorax oc-
curring within 72 hours from the onset of
menstruation.2 However, the recurrent char-
acter in relation with the immediate premen-
strual period has also been reported.3,4 It has
been recently shown that a recurrent endo-
metriosis-related pneumothorax might be ob-
served also in the intermenstrual period.5
Therefore it has been suggested that thoracic
endometriosis should be suspected in any
case of recurrent pneumothorax in women of
reproductive age, even when episodes occur
out of the menstrual period.5
Second, Korom and associates1 proposed
plication of the portion of diaphragm in-
volved by endometriosis rather than excision
and repair. Furthermore, in their opinion hor-
monal therapy should be considered as a sec-
ondary therapeutic option to be used in case
of failure of surgical intervention: they
adopted this strategy in one of the 3 patients.
We do not agree with these suggestions. In
our opinion resection of all the visible lesions
(when technically feasible) should be carried
out not only to optimally treat the cause of
pneumothorax but also to avoid further in-
trathoracic spread of the disease.2 In the ab-
sence of a hormonal treatment, endometrial
implants (which are left in place by simple
plication) would continue to undergo cyclical
changes, with possible consequences in terms
of partial diaphragmatic disruption and for-
mation of new holes. We think that patients
should be offered the best chance of cure
when the disease is first diagnosed. For this
reason, we proposed surgical excision of the
diseased structures, pleurodesis, and a short
course of hormonal treatment.2 Pleural sym-
physis takes some weeks to be effective after
surgical intervention, and if menstruation oc-
curs before pleurodesis is achieved, a recur-
rence of pneumothorax will be likely.
Marco Alifano, MD
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Jean François Regnard, MD
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Reply to the Editor:
My colleagues and I thank Dr Alifano for
his interest in our work and would like to
respond to the comments brought forward
concerning our recently published review
on catamenial pneumothorax (CPT).1 First,
they debate the classic description of CPT.
As a time-honored working definition, this
phenomenon has been described on the ba-
sis of its temporal relationship with the
menstrual cycle. In the majority of pub-
lished cases, CPT has been reported to
reach clinical significance (culminating in
the diagnosis of spontaneous pneumotho-
rax) within 72 hours of the beginning of the
menstrual flow. Yet as Dr Alifano has
pointed out, there are some reports on CPT
being diagnosed beyond this strict time-
frame.2 Because we believed the same, we
have refrained from quoting this arbitrary
72-hour definition but rather stated that
each episode of CPT is associated with the
menstrual flow. Being aware of the patho-
physiologic background, it is obvious that
the individual relevance of a developing
pneumothorax might be subject to a wider
chronologic margin.
Second, Dr Alifano criticizes our ther-
apeutic approach in CPT. He suggests “ex-
cision of all visible lesions (when techni-
cally feasible).” Similarly, we stated the
following: “All accessible lesions should
be excised, and plication is recommended
to seal and strengthen this area.” In contrast
to our approach, Dr Alifano adds a
6-month course of hormonal therapy to his
surgical therapy in all cases. Describing
this therapeutic regimen in a recent publi-
cation, Alifano and associates3 cite only
one (early) recurrence out of 8 treated pa-
tients; however, in this study the mean
follow-up time is 6.6 months, with a range
from 2 to 15 months. In contrast, on the
basis of our experience and the world lit-
erature, abrogating the ovarian steroid gen-
esis in mature women with CPT constitutes
a significant alteration of the hormonal
equilibrium in these patients. Without data
on the long-term follow-up with these
courses, we believe that abrogating the
ovarian steroid genesis in a young woman
is not a justifiable first-line approach for
this clinical picture because excision and
plication of the diaphragm might prevent
recurrence of pneumothorax, as reported in
several cases.
Walter Weder, MD
Division of Thoracic Surgery
University Hospital of Zurich
Ramistrasse 100
Zurich CH-8091, Switzerland
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Hematocrit trial
To the Editor:
We read with interest the report by
Ootaki and associates,1 as well as the
correspondence by Shuhaiber2 in refer-
ence to the article by Habib and col-
leagues.3 Ootaki and coworkers1 applied
a transfusion protocol in which blood
was not transfused during cardiopulmo-
nary bypass unless hematocrit was less
than 15%. They found that patients with a
hematocrit of less than 20% had a higher
lactate level than patients with a higher
hematocrit but imply that this has no
functional significance.
In their critique of the article by Habib
and associates,3 which emphasized the
value of the lowest hematocrit as a predic-
tor of outcome, Shuhaiber2 implied that a
hematocrit of 20% is a useful transfusion
trigger. They also called for a prospective
randomized study of hematocrit, as did
Habib’s group.
At the 2002 meeting of the American
Association for Thoracic Surgery, we pre-
sented the results of a prospective random-
ized trial of 2 hemodilution strategies.4
This study was shut down by the Data and
Safety Monitoring Board of the National
Institutes of Health because of a strongly
positive outcome. Infants who had a mean
hematocrit of 27.8%  3.2% (n  73) had
significantly better motor skills at 1 year of
age relative to patients whose lowest he-
matocrit on bypass was 21.5%  2.9%
(n  74). A significantly greater percent-
age of patients at 1 year of age were clas-
sified as developmentally delayed with re-
spect to motor skills relative to patients
perfused at a higher hematocrit. The lactate
level 1 hour after bypass was significantly
lower with the higher hematocrit.
The findings of our prospective ran-
domized study are consistent with several
previous reports derived from our labo-
ratory work in this area.5-7 Studies using
near-infrared spectroscopy suggest that
acute hemodilution during cardiopulmo-
nary bypass results in cerebral hypoxia. It
is important to remember, before discard-
ing the significance of our clinical trial as
being irrelevant to adults because it was
performed in infants, that the mature
brain is significantly more sensitive to
hypoxic injury than the neonatal and in-
fant brain. Nevertheless, we strongly en-
dorse the call for a prospective random-
ized trial of hematocrit in adults
undergoing cardiopulmonary bypass, in-
cluding sensitive end points such as as-
sessment for cognitive dysfunction. In
the meantime, we strongly recommend
that a hematocrit of at least 25% and
preferably closer to 30% should be used
during cardiopulmonary bypass.
Richard A. Jonas, MD
Department of Cardiovascular Surgery
Children’s National Medical Center
Washington, DC 20010
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Randomized prospective trial for
blood transfusion during adult
cardiopulmonary bypass surgery
To the Editor:
Hemoglobin dilution is an expected physi-
ologic response during cardiopulmonary
bypass (CPB) surgery. Current contro-
versy, however, centers around this ques-
tion: what is a safe hematocrit level during
CPB before the patient sustains less than an
expected outcome? The main reason for the
lack of consensus regarding blood transfu-
sion may stem from the lack of a direct
cause (hematocrit level) and effect (mor-
bidity and mortality) relationship or an as-
sociation or both causality and association.
Although it has been found that low pre-
operative hemoglobin levels are correlated
with poorer outcome,1 it does not mean
that correcting this number will result in
improved outcome. This same argument
holds true for intraoperative hematocrits
with the understanding that new-onset in-
traoperative anemia is reversible and
mainly caused by dilution, whereas preop-
erative anemia is pathologic and mainly
caused by nondilutional processes. Also,
despite understanding the reversibility con-
cept, most decisions of intraoperative
transfusion stem from personal and institu-
tional experience, with no defined dimen-
sions. In May 2004, the National Heart,
Lung, and Blood Institute working group
published an executive summary regarding
future directions in cardiac surgery.2 Cre-
ating a cardiovascular surgery clinical re-
search network was one of the pillars, and
I hope that the working group and the Na-
tional Institutes of Health–sponsored work-
shop for neurocognitive changes after car-
diac surgery will consider this trial an
important direction toward filling an exist-
ing critical gap.
Why Is a Hematocrit Trial Timely?
The patient’s physiologic status must be
the underlying cause for a transfusion, and
the outcome of the transfusion (effect)
must also be considered. The practicing
surgeon, including those in training, is cur-
rently confused with the paradigm of cause
and effect that seems to argue that mortal-
ity is higher among patients with low he-
matocrit (25% in women and 23% in
men3,4) and high hematocrit (34%).5
Randomization is lacking in the adult car-
diac surgery group thus far, despite a clear
benefit of increased hematocrit for neuro-
logic outcome in pediatric heart surgery
(mean intraoperative hematocrit: 27.8% vs
21.5%).6
Moreover, despite the benefit of in-
creased oxygen-carrying capacity with
increased hematocrit, we must be aware
that blood transfusions expose patients to
a variety of potential cellular and hu-
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